Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer

Autor: Justine Baek, Lawson Eng, Devalben Patel, Grainne M. O'Kane, Mindy Liang, R. Walton, RuiQi Chen, Elliot Charles Smith, Sze Wah Samuel Chan, Geoffrey Liu, Catherine Labbé, Penelope A. Bradbury, Katrina Hueniken, Shirley Xue Jiang, Adrian G. Sacher, M. Hurry, Alexandra McCartney, Catherine Brown, Wei Xu, Natasha B. Leighl, Frances A. Shepherd
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
Lung Neoplasms
medicine.medical_treatment
urologic and male genital diseases
0302 clinical medicine
Carcinoma
Non-Small-Cell Lung
hemic and lymphatic diseases
health economics
Osimertinib
Epidermal growth factor receptor
Original Research
education.field_of_study
biology
Disease Management
Middle Aged
real‐world
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Rash
ErbB Receptors
Treatment Outcome
030220 oncology & carcinogenesis
Female
medicine.symptom
medicine.drug
Cohort study
medicine.medical_specialty
health utility scores
Population
lcsh:RC254-282
03 medical and health sciences
Gefitinib
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Lung cancer
education
Protein Kinase Inhibitors
Aged
Neoplasm Staging
Chemotherapy
business.industry
Clinical Cancer Research
Patient Acceptance of Health Care
medicine.disease
lung cancer
030104 developmental biology
Mutation
biology.protein
EGFR mutation
business
Zdroj: Cancer Medicine, Vol 8, Iss 18, Pp 7542-7555 (2019)
Cancer Medicine
ISSN: 2045-7634
DOI: 10.1002/cam4.2603
Popis: Background As the treatment landscape in patients with non‐small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFRm) continues to evolve, real‐world health utility scores (HUS) become increasingly important for economic analyses. Methods In an observational cohort study, questionnaires were completed in EGFRm NSCLC outpatients, to include demographics, EQ‐5D‐based HUS and patient‐reported toxicity and symptoms. Clinical and radiologic characteristics together with outcomes were extracted from chart review. The impact of health states, treatment type, toxicities, and clinical variables on HUS were evaluated. Results Between 2014 and 2018, a total of 260 patients completed 994 encounters. Across treatment groups, patients with disease progression had lower HUS compared to controlled disease (0.771 vs 0.803; P = .01). Patients predominantly received gefitinib as the first‐line EGFR tyrosine kinase inhibitor (TKI) (n = 157, mean‐HUS = 0.798), whereas osimertinib (n = 62, mean‐HUS = 0.806) and chemotherapy (n = 38, mean‐HUS = 0.721) were more likely used in subsequent treatment lines. In longitudinal analysis, TKIs retained high HUS (>0.78) compared to chemotherapy (HUS
Real‐world health utility scores (HUS) in epidermal growth factor receptor mutations (EGFRm) non‐small cell lung cancer outpatients were similar between those treated by first‐ and second‐line tyrosine kinase inhibitors, which were superior to chemotherapy. Treatment‐associated toxicities corresponded to HUS of treatment groups.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje